Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Prediction Of Prognosis And Response To Androgen Deprivation Therapy In Intermediate To High-risk Prostate Cancer Using 18f-fdg Pet/ct Radiomics.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Prediction Of Prognosis And Response To Androgen Deprivation Therapy In Intermediate To High-risk Prostate Cancer Using 18f-fdg Pet/ct Radiomics.

Related Experiment Video

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Prediction of Prognosis and Response to Androgen Deprivation Therapy in Intermediate to High-Risk Prostate Cancer Using ¹⁸F-FDG PET/CT Radiomics.

Jianyi Qiao¹, Bitian Liu², Jun Xin³

¹Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.

Academic Radiology

|July 17, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study shows that 18-fluoro-2-deoxyglucose (18F-FDG) PET/CT radiomics can predict prostate cancer prognosis. The developed radiomics nomogram demonstrates potential for clinical use in managing intermediate to high-risk patients.

Keywords:

(18)F-FDG PET/CT Androgen Deprivation Therapy Prognosis Prostate Cancer

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

Nuclear medicine and oncology
Radiomics and medical imaging analysis
Prognostic biomarker development

Background:

Prostate cancer (PCa) prognosis prediction is crucial for treatment decisions.
Current methods may not fully capture the complexity of intermediate to high-risk PCa.
18-fluoro-2-deoxyglucose (18F-FDG) PET/CT offers functional imaging insights.

Purpose of the Study:

To predict prognosis in intermediate to high-risk prostate cancer (PCa) using 18F-FDG PET/CT radiomics.
To develop and validate a radiomics nomogram for PCa prognostication.
To perform subgroup analyses for patients receiving androgen deprivation therapy (ADT) and those with metastatic PCa.

Main Methods:

Retrospective analysis of 104 intermediate to high-risk PCa patients who underwent 18F-FDG PET/CT.

Development of two PET/CT radiomics models (multivariate logistic regression and ensemble learning).

Creation of a radiomics nomogram integrating radiomics score and tumor-to-liver ratio (TLR).

Main Results:

Radiomics model A (8 radiomics features) achieved an AUC of 0.844 (training) and 0.804 (testing).
The radiomics nomogram showed good prognostic accuracy with an AUC of 0.827 in the testing set.
Subgroup analyses for ADT and metastatic PCa yielded AUCs of 0.845 and 0.807, respectively.

Conclusions:

The 18F-FDG PET/CT radiomics nomogram is effective in predicting prognosis for intermediate to high-risk PCa.
This nomogram shows potential for clinical application in PCa management.
Radiomics analysis of 18F-FDG PET/CT is a promising tool for PCa prognostication.